The abstract is read at the publisher; the summary is JClub's.
Concurrent neoadjuvant epirubicin/ifosfamide with preoperative radiotherapy in high-risk soft-tissue sarcoma is feasible, with similar hematologic toxicity and a higher RECIST response (20.3% vs 9.8%).
- Why it matters: The trial addresses whether adding radiotherapy during epirubicin/ifosfamide can be tolerated and whether it improves early tumor response in localized high-risk disease.
- What they did: In ISG-STS 1001, 287 patients were analyzed, including 146 receiving preoperative RT; outcomes compared the concurrent ChT/RT group versus preoperative ChT alone, assessing dose intensity, grade ≥3 hematologic toxicity, acute RT toxicity, postoperative complications, and RECIST response.
- The result: Dose intensity was >90% in both groups and hematologic toxicities were comparable; however, wound dehiscence (9% vs 3.5%; P = 0.06) and seroma (10.4% vs 2.8%; P = 0.01) were higher with concurrent treatment, while RECIST response was linked to preoperative RT (P = 0.02).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.